TNF and COVID-19: Anti-cytokine drugs, such asIL-6 receptor inhibitors and TNF-α inhibitors, require more in-depth research to reach a consensus about the best timing of these therapies when administering the COVID-19 vaccine, although preliminary data suggest they minimally hamper vaccine-induced immunogenicity.